Cover Image


Japan Generics Market Analysis

出版商 RNCOS E-Services Pvt. Ltd. 商品编码 231240
出版日期 内容信息 英文 55 Pages
Back to Top
日本的学名药市场分析 Japan Generics Market Analysis
出版日期: 2012年02月01日 内容信息: 英文 55 Pages



第1章 分析师的见解

第2章 分析方法

第3章 近几年的市场动向

  • 保险药局与DPC(诊断群各分类综合评价制度)引进医院:学名药的大贡献
  • 日本市场:对大型医药品企业来说学名药成为新的核心市场
  • 非专利药品癌症治疗药:急剧成长预测

第4章 人口统计概况

第5章 日本的医药品市场预测(到2014年为止)

第6章 日本的学名药市场概况

  • 医疗费用支出
    • 不同疾病·各年龄层的支出额
  • 学名药的普及率
  • 学名药市场预测(到2014年为止)
  • 非专利药品处方药和非专利药品成药
  • 流通系统
    • 各医疗机关
    • 各销售管道
  • 近几年的学名药的销售情形

第7章 消费者行动分析

  • 患者方面的意见
  • 医生·药剂师方面的意见

第8章 法规环境

  • 卫生署(MHLW)所扮演的角色
  • 学名药的认证及销售许可时的主要必要条件
  • 专利制度

第9章 政府的主要促进策略

第10章 市场机会的评估

  • 专利失效
  • 治疗治疗

第11章 主要企业

  • Nichi-Iko Pharmaceutical
  • 泽井制药
  • 大洋药品工业
  • 东和药品
  • Meiji Seika
  • Nippon Chemipher




Japan is the world's second largest pharmaceutical markets in the world, but due to public perception, the share of generic drugs has remained low in it. However, worried over rising healthcare expenses and high mortality rates, the government has now been playing a vital role in promoting generics. The patent expiry of branded drugs and active ingredients will also act as a strong growth driver for the market in future. According to the findings of our latest report, the generics market in Japan stood at around US$ 9 Billion in 2010. It estimates that the growth in generic drugs will outshine the expansion in overall pharmaceutical market.

According to "Japan Generics Market Analysis", Japan is expected to be the next generic hub, and cancer related generics exhibit vast potential. The report finds out how vital is the role of National Health Insurance (NHI) pharmacies and Diagnosis Procedure Combination (DPC) hospitals in the industry development. It was observed that the DPC hospitals, in particular, have been growing at a robust rate, promoting generics penetration. We also found that ethical generics hold the majority share in the generic drugs market.

A detailed demographic analysis was carried out in the research that revealed that the population aged 65 years and above accounts for maximum healthcare-related expenditures in Japan, and hence becomes the target population for generics promotion. Further, a meticulous disease and age-wise segmentation has provided the holistic understanding of the healthcare-related demand parameters prevailing in the country.

The government in Japan has taken several initiatives to ensure growth and promotion of generics industry in the country. Recently, special premium-based incentives have been given to pharmacists on generic promotion. In near future, the government plans to bring in more reforms in medical care system. Our research talks about such revisions and reforms briefly to present a balanced outlook of the industry to clients. Analysis of current trends, profiles of key players in the Japanese generic market, and recent developments in the industry have also been included in the comprehensive study.

Table of Contents

1. Analyst View

2. Research Methodology

3. Recent Market Trends

  • 3.1 NHI Pharmacies and DPC Hospitals to Contribute Majorly in Generics
  • 3.2 Japan: Next Generic Hub for Pharma Majors
  • 3.3 Cancer Generics Projected for Exorbitant Growth

4. Demographics Profile

5. The Japanese Pharmaceutical Market Outlook to 2014

6. The Japanese Generic Drugs Market Overview

  • 6.1 Healthcare Expenditure
  • 6.1.1 Expenditure by Disease and Age Group
  • 6.2 Generics Penetration
  • 6.3 Generics Market Outlook to 2014
  • 6.4 Ethical vs OTC Generics
  • 6.5 Distribution System
  • 6.5.1 By Medical Institution
  • 6.5.2 By Distribution Channel
  • 6.6 Recent Generic Launches

7. Consumer Behavior Analysis

  • 7.1 Patients View
  • 7.2 Physicians and Pharmacist View

8. Regulatory Environment

  • 8.1 Role of MHLW
  • 8.2 Key Requirements for Generics Approval and Marketing Authorization
  • 8.3 Patent System

9. Key Government Initiatives

10. Opportunity Assessment

  • 10.1 By Patent Expiration
  • 10.2 By Therapeutic Treatment

11. Key Players

  • 11.1 Nichi-Iko
  • 11.2 Sawai Pharmaceuticals
  • 11.3 Taiyo Pharmaceutical
  • 11.4 Towa
  • 11.5 Meiji Seika
  • 11.6 Nippon Chemipher

List of Figures:

  • Figure 3-1: Cancer Mortality Rate (per 100,000 Population), 2000 & 2010
  • Figure 5-1: Pharmaceutical Market (Billion US$), 2010-2014
  • Figure 5-2: Share of Generics in Pharmaceutical Market (2011)
  • Figure 5-3: Pharmaceutical Sales by Facility (%), 2009
  • Figure 6-1: Healthcare Expenditure (Billion US$), 2010 & 2015
  • Figure 6-2: Percentage Distribution of Healthcare Expenditure by Diseases for Population Aged below 65 (2008)
  • Figure 6-3: Percentage Distribution of Healthcare Expenditure by Diseases for Population Aged 65 and Above (2008)
  • Figure 6-4: Share of Generic Drugs in Pharmaceuticals Market w.r.t Developed Countries (2009)
  • Figure 6-5: Generic Drugs Market (Billion US$), 2010-2014
  • Figure 6-6: Market Share of Generic Drugs Manufacturers (2010)
  • Figure 6-7: Generic Drugs Market by Segment (%), 2009
  • Figure 6-8: Generic Drugs Market by Medical Institution (%), 2008 & 2009
  • Figure 6-9: Number of DPC Hospitals (FY 2007 to FY 2010)
  • Figure 6-10: Generic Drugs Market by Distribution Channel (%), 2008 & 2009
  • Figure 11-1: Sawai Pharmaceutical - Sales by Therapeutic Category (%), FY 2010
  • Figure 11-2: Towa Pharmaceutical - Sales by Therapeutic Category (%), Mar 2011

List of Tables:

  • Table 3-1: Recent Industry Activities in Cancer Generics
  • Table 4-1: Demographic Characteristics (2010 & 2015)
  • Table 6-1: Recent Generic Drugs Launch of Key Players (2011)
  • Table 8-1: Application Fee for Manufacturing and Marketing of Generics (JPY)
  • Table 9-1: Key Measures for Generic Drugs Promotion
  • Table 10-1: Patent Expiry of Key Drugs in Japan (2012-2015)
Back to Top